Acrivon Therapeutics, Inc. (ACRV): Total Assets
$129.72M
As of 2025-12-31
$99.09M
As of 2026-06-30
-10.5%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $129.72M | -34.0% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $196.59M | +42.2% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $138.26M | -23.7% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $181.23M | +70.0% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $106.59M | n/a | 2023-03-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $129.72M | -34.0% |
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | $130.94M | +12.2% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $131.44M | -35.1% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $127.04M | -38.7% |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $138.19M | -1.2% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $138.29M | +43.5% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $119.59M | -44.3% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $140.72M | +133.4% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
Compare ACRV, CTXR, SLN, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗